Amgen Inc. (AMGN)
| Market Cap | 177.14B |
| Revenue (ttm) | 35.97B |
| Net Income (ttm) | 7.01B |
| Shares Out | 538.48M |
| EPS (ttm) | 12.93 |
| PE Ratio | 25.43 |
| Forward PE | 15.42 |
| Dividend | $10.08 (3.06%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 1,897,047 |
| Open | 324.09 |
| Previous Close | 324.30 |
| Day's Range | 323.55 - 329.20 |
| 52-Week Range | 261.43 - 346.38 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 321.69 (-2.21%) |
| Earnings Date | Feb 3, 2026 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $321.69, which is a decrease of -2.21% from the latest price.
News
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment.
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO says weight loss drug can address 'patient persistence issue'
Amgen CEO Bob Bradway told CNBC's Jim Cramer he thinks his company's obesity drug can help patients maintain weight loss, which he indicated is a challenge. "We think we can address one of the reasons...
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 ...
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen says MariTide helped trial patients maintain weight loss
An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a second mid-stage trial in diabetes patients showed that it lowered their blood...
Amgen to announce data on obesity drug MariTide at healthcare conference
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if ...
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive...
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Jan. 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2026 J.P.
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
On Tuesday, Amgen Inc. (NASDAQ: AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisiti...
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites
The Dow Jones Industrial Average hit record all-time highs in 2025 with many of the components ending the year higher. Along with serving as a well-known barometer of overall market health, the index ...
These three ‘Dogs of the Dow' stocks are must-own for 2026
The “Dogs of the Dow” strategy has staged a comeback, and Kevin Simpson of Capital Wealth Planning believes 2026 could be another strong year. After a 17% gain in 2025, beating the broader Dow's perfo...
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Can Amgen Sustain Its Rally In 2026
Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif. , Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action aga...
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...